Search
Displaying 441–450 of 689 for “retinitis clinical trial”
-
To make a bigger impact on our mission to turn early research into clinical trials for people with IRDs and dry AMD, the Foundation will grow its network of collaborators and partners.
-
Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy
Foundation NewsGyrate atrophy is an inherited retinal disease—causing progressive vision loss. GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.
-
Eye on the Cure Podcast | Episode 50: Rachel Huckfeldt, MD, PhD
Eye on the CureJuly 21, 2023. Rachel Huckfeldt, MD, PhD, a clinical researcher and assistant professor of ophthalmology at Mass Eye and Ear, talks with host Ben Shaberman about caring for patients with inherited retinal diseases (IRD), the challenges and opportunities with clinical trials, and the educational and professional journey that led her to the IRD research field.
-
Disease
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive vision loss.
-
Your Dollar Makes a Difference
Foundation NewsAt the Foundation Fighting Blindness, a dollar is more than just a dollar – it’s a path to transforming lives. But just where does your donation go?
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2022 (July 1, 2021–June 30, 2022)
-
Foundation News
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
Foundation News
The inaugural credit-based event will include education on inherited retinal diseases, physician resources, and current clinical trials.
-
What Does the Foundation's Statement of Financial Position Mean?
First and foremost, it means the Foundation Fighting Blindness (FFB) is in a strong position to continue to fund the most promising research on potential cures for retinal degenerative diseases and to help bring groundbreaking discoveries to clinical trials and the U.S. Food and Drug Administration (FDA) approval process.
%20(9).png)
